Day: October 18, 2022

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating...

Lewisville, TX, Oct. 18, 2022 (GLOBE NEWSWIRE) — Parsec Capital Acquisitions Corp. (NASDAQ: PCX, PCXCU, PCXCW) (the “Company”), a special purpose acquisition corporation sponsored by Parsec Acquisitions Sponsor, LLC, announced the execution of an agreement and plan of merger with Enteractive Media Inc. of Calgary, Alberta on October 13, 2022 (“Enteractive Media” and the transaction, the “Business Combination”). The transaction has been approved by the Board of Directors of both the Company and Enteractive Media and is expected to be consummated in the fourth quarter of 2022, subject to regulatory and stockholder approval by the stockholders of the Company and the stockholder of Enteractive Media and the satisfaction of certain other customary closing conditions. Enteractive Media Inc., established in 2013, is a business that acts...

SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna, will present at the iPSC-Derived Immunotherapies Congress, taking place October 18-19, 2022 in Boston. Details of Presentation Title: Avoiding Vector Integration Using mRNA Vectorization of Reprogramming and Gene Editing ProteinsPresenter: Matt Angel, Ph.D., Interim Chief Executive Officer of EternaDate: October 18, 2022Time: 3:10 p.m. ETLocation: Hilton Boston Back Bay Hotel, 40 Dalton St., Boston, Massachusetts 02115 About Eterna TherapeuticsEterna is focused on developing advanced therapies using state-of-the-art mRNA cell...

SUGAR LAND, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) — CVR Partners, LP (NYSE: UAN), a manufacturer of ammonia and urea ammonium nitrate (UAN) solution fertilizer products, plans to release its third quarter 2022 earnings results on Monday, Oct. 31, after the close of trading on the New York Stock Exchange. The Partnership also will host a teleconference call on Tuesday, Nov. 1, at 11 a.m. Eastern to discuss these results. This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Partners’ website at www.CVRPartners.com. For investors or analysts who want to participate during the call, the dial-in number is (877) 407-8029. The webcast will be archived and available for 14 days at https://edge.media-server.com/mmc/p/d34knpg9. A repeat of the call also...

HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that, as per protocol design, it is voluntarily pausing new patient enrollment in the company’s Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas. The pause in new patient enrollment is due to a metastatic FET-rearranged sarcoma patient death that was classified as a suspected unexpected serious adverse reaction (SUSAR). Upon review of the SUSAR and available information by the company’s independent Safety Review Committee for the clinical trial, patients currently receiving seclidemstat treatment may continue treatment...

FortiSASE is the only offering to integrate cloud-delivered SD-WAN connectivity with cloud-delivered security (SSE) to enable the industry’s most flexible secure private access SUNNYVALE, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) — John Maddison, EVP of Products and CMO“Fortinet delivers the most integrated single-vendor SASE solution available, uniquely converging best-of-breed networking and best-of-breed security that are unified by a single operating system. The latest cloud-delivered enhancements to FortiSASE further strengthen our ability to enable consistent security and user experience no matter where users and applications are distributed.” News Summary Fortinet® (NASDAQ: FTNT), the driving force in the evolution of cybersecurity and the convergence of networking and security, today announced significant cloud-delivered...

An Integration with ExamWorks’ U.S. IME Division Enables Duck Creek Claims Users to Manage Their Independent Medical Examination Service Referral Requests Boston, Oct. 18, 2022 (GLOBE NEWSWIRE) — Duck Creek Technologies (NASDAQ: DCT), the intelligent solutions provider defining the future of property and casualty (P&C) insurance, today announces a cloud-based integration with ExamWorks’ U.S. IME division to offer Independent Medical Examinations (IMEs) to P&C and legal customers. Embedded within the Duck Creek platform, this Anywhere Enabled Integration (AEI) gives customers the ability to send relevant claimant information and medical records associated with the IME request for workers’ compensation, auto, and liability claims. “We are thrilled to partner with a leading provider of independent medical exams and offer...

A Multicenter Open Label Study of QRX003 Topical Lotion in Netherton Syndrome Patients Who Are Currently Receiving Systemic Biologic Therapy. ASHBURN, Va., Oct. 18, 2022 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces that it is initiating a second clinical trial in Netherton Syndrome patients. This multicenter, open label study will be being conducted under Quoin’s currently open U.S. Investigational New Drug (IND) Application and will assess QRX003 topical lotion in Netherton patients who are currently receiving treatment including systemic therapy for symptomatic relief. QRX003 will be applied once daily over a twelve-week period, to pre-designated areas of the patient’s body. A number of different clinical...

SUGAR LAND, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) — CVR Energy, Inc. (NYSE: CVI) plans to release its third quarter 2022 earnings results on Monday, Oct. 31, after the close of trading on the New York Stock Exchange. The Company also will host a teleconference call on Tuesday, Nov. 1, at 1 p.m. Eastern to discuss these results. This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Energy’s website at www.CVREnergy.com. For investors or analysts who want to participate during the call, the dial-in number is (877) 407-8291. The webcast will be archived and available for 14 days at https://edge.media-server.com/mmc/p/bbxgdpdi. A repeat of the call also can be accessed for 14 days by dialing (877) 660-6853, conference ID 13733765. CVR Energy’s third...

TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) — Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (“AFCP” or the “Company”), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to report that all resolutions put forth at the special meeting of shareholders held today, October 17, 2022 (the “Special Meeting”) have been duly passed. At the Special Meeting, a total of 5,255,746 AFCP common shares held by individuals that were not advantaged by the proposed amendments to the warrants and stock options (as described in the Company’s management information circular dated September 16, 2022) (the “Amendments”) were present in person or by proxy, representing approximately 3.04% of the AFCP common shares issued and outstanding and entitled...